Denali Capital Extends Deadline on Longevity Biomedical Deal

Denali Capital Acquisition said $50,000 was deposited into its trust to extend the deal deadline by another month to April 11. The SPAC has a merger agreement with Longevity Biomedical, which is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.” 

Redemptions have removed most of the SPAC’s trust, although Longevity Biomedical in August agreed to waive the deal’s $30 million cash closing condition. Denali also has an $18 milion PIPE commitment with FutureTech Capital to support the transaction.

The deal was announced in January 2023. Read more.

Total
0
Shares
Related Posts
TB SA Acquisition
Read More

TB SA Acquisition Calls it Quits

TB SA raised $200 million in an IPO two years ago with plans at the time to identify a target with a focus on African companies that promote Environmental, Social and Governance (“ESG”) principles.